Daily financial advice:
“Kechuang Biotechnology surged 125.4% in less than an hour after its listing, and the Science and Technology Innovation Board finally took the lead.”
“On October 8, 2021, Kechuang Biotech (*****.SH) was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. As of now, Kechuang Biotech has reported 2,295.09 yuan per share, an increase of 125.4%. It opened on the first day of listing. The collective bidding period soared by more than 100%. As "the first stock in brain-computer connection and innovative drugs," Kechuang Biotech set a record for the highest market value of a new A-share stock this year.
Kechuang Biotechnology has the highest issue price in the history of A-shares, and winning the first lottery requires more than 500,000 yuan in funds.
So far, successful users of Kechuang Biotechnology have earned more than 500,000 yuan per lottery. This stock is also the most profitable new stock in the history of the A-share market.
Kechuang Biotechnology is a biomedical research and development company that provides brain-computer connection chip patent licensing, alpha-endorphin manufacturing and patent licensing.
Since its establishment, the company has continuously achieved breakthrough technological innovations in the fields of innovative drugs and brain-computer connection. It also has a full set of patents for brain-computer connection chips and patents for industrialized large-scale production of endorphins, and has large-scale endorphin production capabilities.
The market believes that in the context of the overall downturn in the biopharmaceutical market, the company's issuance price is relatively high, and the stock price's superior performance is inseparable from its moat.
The strategy team of Guotai Junan Securities stated that from a strategic perspective, the current pharmaceutical market has reached a stage of differentiation: while industry trends continue and growth space still needs to be realized, we continue to be optimistic about the biopharmaceutical industry in the medium and long term, but we need to choose a moat and innovative capabilities. biopharmaceutical companies. Biomedical companies like Kechuang Biotech still have investment opportunities. "
The leader of the main board is Moutai, and the leader of the GEM is CATL. Previously, investors had pinned their hopes on SMIC to become the leader of the Science and Technology Innovation Board.
However, SMIC, which has been falling all the way, is difficult to meet expectations, and its market value of less than 400 billion cannot compete with CATL and Moutai.
"Science and Technology Biotechnology is the overall leader of the metaverse. We can see 3,000 yuan in the short term, 5,000 yuan in the mid-term, and 10,000 yuan in the long term!"
In the comments below the Daily Financial Consulting, this refers to drinking too much and pressing zero on the calculator.
"Why didn't I win the lottery (tears) (tears) (tears)? I was just one digit short of winning, and half a million just passed me by (tears)"
"Zheng Li is a real genius. The company's valuation in the three years since he started his business has approached one trillion yuan."
"I think the price is not high at all. I bought one and kept it for my son."
"Kechuang Biotech has several good things that have not yet been revealed. When will the brain-computer connection technology be sold to Europe and the United States? The development progress of new drugs. The application of brain-computer connection technology in other fields. The possible profits from combining brain-computer connection technology with VR. Too much."
"800 billion is just the current valuation of Kechuang Biotech. If we want to calculate future growth, no A-share company can match Kechuang Biotech."
"Kechuang Biotechnology has a moat comparable to Pien Tze Huang, stronger growth potential than SMIC, and better net profit margins than Amic. This valuation is completely underestimated!"
"When will A-shares label Kechuang Biotechnology as the Metaverse? It is not just a pharmaceutical and semiconductor company, it is also the purest Metaverse concept stock!"
"Will the trading suspension be triggered today?"
After a new stock is listed on the Science and Technology Innovation Board, if its price differs by more than 30% from its opening price, it will be subject to an intraday trading halt.
"This price is too high. The price of one hand is more than 200,000 yuan. Xiaosan has no chance to participate. It is completely concentrated in the hands of institutions."
"For such a large market to rise so crazily on the first day, it's definitely institutions buying in large amounts. If retail investors can't lift the sedan at all, I personally am still very optimistic about the future development of Kechuang Biotechnology."
Whether it is the price, the hot market, or the legendary nature of science and technology biology itself, the enthusiasm of stock investors for discussion is extremely high.
Ke Chuang Bio's stock bar was directly ranked first in the popularity rankings.
.....
The final closing price of Kechuang Biotech was set at 2,408.01 yuan, making it the company with the highest A-share unit price at the moment, and the only company in the A-share market with a share price of more than 2,000 yuan, the other being Moutai.
At the celebration banquet of the Science and Technology Creation Organization in the evening, the noisy atmosphere almost broke through the ceiling.
Li Miaomiao didn't drink much. She was a little unaccustomed to people around her being overly attentive to her.
The colleagues around her also knew her relationship with Zheng Li, and no one dared to show any inappropriate thoughts towards her.
After it was over, Li Miaomiao asked the driver to take her and Li Shuyao home.
Although Li Shuyao was an intern in this project, because she was Li Miaomiao's sister, she was also invited to the celebration banquet.
Regardless of Li Shuyao's family background, her identity as Li Miaomiao's sister, and her academic qualifications and appearance, she has become the target of men at the celebration banquet.
Many financial men do not get married in their thirties, and Li Shuyao is almost a perfect marriage partner for them.
After sitting in the back seat of the car, Li Shuyao sat up straight and said, "It feels great to become rich in one day, right?"
Li Miaomiao was startled: "Are you not drunk?"
Li Shuyao smiled naively: "How much red wine did you drink? You are still far from being drunk~"
"I'll be relying on you from now on. What percentage of Zhengli's shares account for a company with a market value approaching one trillion?"
Li Miaomiao: "About sixty-three."
Li Shuyao shook her head: "It's really an exaggeration. She is only in her early twenties and her net worth is already as high as 500 billion RMB."
"Zuckerberg is nothing more than that."
"You met Zheng Li because you won one hundred five million lottery tickets in a row. You were so lucky that I ascended to heaven with my chickens and dogs."
"This afternoon, people from CICC said that I can go to their investment banking department after graduation."
Li Miaomiao was happy for her sister. She applauded repeatedly: "Congratulations on getting what you wanted!"
“CICC is a good platform.”
Li Shuyao sighed and said, "If it were me in the past, I would definitely be very happy and want to celebrate with my friends."
"But now that I have seen my sister who grew up with me become a billionaire in one day, I feel like my efforts are useless."
"We grew up together and have a good relationship, and rarely have arguments, but there will still be jealousy in my heart, and there will be thoughts about why it's not me."
"I know it shouldn't be done, but it's normal and human."
"After what I have experienced, if I want to return to a normal nine-to-five life, I feel that it will take a while to cultivate."
Li Miaomiao smiled: "I never thought before. When Zheng Li and I went to Suzhou to start a business, our best estimate was that we could successfully market endorphins."
"It can keep the company alive and functioning normally."
"I never thought that Kechuang Biotech could reach this stage now."
